Clinical Trials
11 trialsNCT07052305 2026-05-13
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Recruiting
NCT07200089 2026-04-07
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT05075603 2025-10-23
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NeoImmuneTech
Phase 1 Completed
NCT04588038 2025-02-14
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
University of California, San Francisco
Phase 1 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT04893018 2024-06-27
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Unknown
NCT04054752 2023-11-02
Vaccine Response With NT-I7
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02659800 2023-10-06
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03733587 2020-05-14
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Genexine, Inc.
Phase 1 Completed
NCT03478995 2020-05-11
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Genexine, Inc.
Phase 1 Completed